Comprehensive In Vitro Proarrhythmia Assay (CiPA)

Currently, the proarrhythmic potential of new drugs is determined by evaluating their effects on the hERG ion channel and the in vivo QT interval. However, due to the overly sensitive nature of these assays, it is believed that many potentially valuable therapeutics have been inadvertently prevented from reaching the clinic.

The comprehensive in vitro proarrhythmia assay (CiPA) is a new strategy proposed by expert working groups sponsored by the Cardiac Safety Research Consortium (CSRC), Health and Environmental Sciences Institute (HESI) and Food and Drug Administration (FDA). This proposal shifts the emphasis away from QT prolongation and focuses on predicting torsadogenic hazard through an expansion of the in vitro component of nonclinical safety evaluation.

Our cardiac ion channel panel, SaVety™ assessment of multiple ion channel effects (MICE) and integrative human cardiomyocyte assays fulfill CiPA recommendations.

Additional Resources

You may also be interested in...

Webinar Replay

View our webinar "Modulation of Tumor Progression by Immune Checkpoint Inhibitors in Syngeneic Murine Tumor Models".

Safety Pharmacology

Established ICH core battery tests and supplementary safety pharmacology models to meet current regulatory requirements and provide data to accurately drive your decision-making process.

Therapeutic Area: Cardiovascular

Charles River is your partner through the entire cardiovascular research process, from discovery through regulatory approval.